Kim, Hyun Young; Okamoto, Takuya; Yokozawa, Takako
Journal of ethnopharmacology
2009Jul ; 124 ( 2 ) :263-9.
PMID : 19397970
ÀúÀÚ »ó¼¼Á¤º¸
Kim, Hyun Young -
Okamoto, Takuya -
Yokozawa, Takako -
ABSTRACT
AIM OF THE STUDY: In the present study, we investigated the effects of Kangen-karyu, a traditional Chinese prescription comprising six herbs, on diabetes. MATERIALS AND
METHODS: Kangen-karyu extract (50, 100, or 200mg/kg body weight) was administered to streptozotocin (STZ)-induced diabetic rats and serum and hepatic biochemical factors, and protein expressions associated with oxidative stress and advanced glycation endproduct (AGE) formation were measured.
RESULTS: The oral administration of Kangen-karyu significantly ameliorated hypertriglyceridemia induced by STZ injection, while serum levels of glucose and total cholesterol were mildly affected. Kangen-karyu also markedly reduced the levels of AGEs and malondialdehyde (MDA), a lipid peroxide product used as an indicator of oxidative stress in both serum and hepatic tissue. In addition, Kangen-karyu dose-dependently lowered the expression levels of N(epsilon)-(carboxymethyl) lysine, one of the major component of AGEs closely associated with the pathogenesis of diabetes and liver cirrhosis, and receptor for AGEs, as well as the expression levels of nuclear factor-kappaB, inducible nitric oxide synthase, and cyclooxygenase-2 (COX-2) associated with oxidative stress. Especially, MDA levels in both serum and hepatic tissue and COX-2 expression increased by STZ were recovered by Kangen-karyu (200mg/kg body weight) to normal levels.
CONCLUSIONS: Kangen-karyu showed favorable effects on hypertriglycemia, AGE formation, and oxidative stress in STZ-treated rats, suggesting beneficial effects on diabetes, diabetic hepatopathy, and liver diseases such as cirrhosis, as well as cardiovascular and cerebrovascular diseases.
Kangen-karyu; Oxidative stress; Advanced glycation endproduct; Streptozotocin
MESH
Angiosperms, Animals, Antioxidants/administration & dosage/pharmacology/*therapeutic use, Blood Glucose/metabolism, Cholesterol/blood, Cyclooxygenase 2/metabolism, Diabetes Mellitus, Experimental/*drug therapy/metabolism, Drugs, Chinese Herbal/pharmacology/*therapeutic use, Glycosylation End Products, Advanced/*metabolism, Hypertriglyceridemia/*drug therapy/metabolism, Hypoglycemic Agents/administration & dosage/pharmacology/*therapeutic use, Hypolipidemic Agents/administration & dosage/pharmacology/therapeutic use, Liver/metabolism, Lysine/metabolism, Male, Malondialdehyde/metabolism, NF-kappa B/metabolism, Nitric Oxide Synthase Type II/metabolism, *Oxidative Stress, *Phytotherapy, Plants, Medicinal, Rats, Rats, Wistar, Triglycerides/blood
¸µÅ©